SEOUL-VIOSYS
18.6.2020 10:30:04 CEST | Business Wire | Press release
Seoul Viosys (KOSDAQ: 092190), a leading compound semiconductor solution provider, announced that its ultraviolet LED Violeds technology – the world’s first UV LED technology proven to sterilize new coronaviruses – has been adopted for the new “Fresh Air” brand of air conditioners produced by Gree Electric Appliances Inc. (Gree), the largest Chinese manufacturer of air conditioners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005326/en/
The Violeds UV LED technology adopted for the Gree “Fresh Air” air conditioner is a differentiated UV technology that provides robust disinfection on the surface of evaporator, as well as sterilization of any indoor airborne contaminants drawn into the air conditioner, including various harmful viruses and bacteria, ensuring that fresh air is continuously discharged. Conventional household air conditioners typically draw outside air into the AC unit, and discharge that air back into the interior after cooling and filtering, where it is continuously recirculated. This recirculation of indoor air may cause a higher risk of infection through aerosol transmission when viruses are present.
Through the results of testing by Guangzhou Institute of Microbiology in China (CGMT), Gree demonstrates that its new “Fresh Air” air conditioner with Violeds UV LED technology has the performance to sterilize 99.15% of viruses and bacteria, 98% of enteroviruses such as EV71 and H1N1, and 99% of staphylococcus albus bacteria. In addition, according to the results of testing conducted in April and May 2020 by the research group of Korea University, Violeds UV LED technology has been proven to sterilize 99.9% of the new coronavirus in 30 seconds. Seoul Viosys provides major customers with optimized UV LED solutions based on these successful testing results.
“Since air conditioning systems operate by circulating indoor air drawn in and discharged again, aerosol transmission is a concern when using these systems. In South Korea, health authorities rolled out a new guideline for citizens to prevent aerosol transmission, which included advising people to open windows every two hours when using their air conditioners,” said Chae Hon Kim, executive vice president of Seoul Viosys. “We offer an optimized solution to simultaneously enable disinfection of viruses in air, as well as air purification by disinfecting the air drawn into air conditioner and eliminating viruses in air using Violeds technology. As more applications adopt the Violeds technology to support healthy life, the cost of UV LEDs is anticipated to be reduced to a level closer to visible white LEDs.”
“Seoul Viosys’ Violeds technology has been adopted not only by the Chinese AC manufacturer Gree, but also by RGF Environmental Group, the leading in-duct air treatment supplier in the U.S. As a result of receiving production approval to supply Violeds products to these two leading global companies, Violeds UV LEDs have clearly been recognized as essential technology for air purifiers and air conditioning systems,” added Kim.
Violeds optical semiconductor technology is a new concept of clean technology developed by Seoul Viosys, starting with a 2005 collaboration with SETi in the U.S. Seoul Viosys’ UV LEDs are used in more than 4,000 patented technology brands worldwide to prevent viruses and bacteria from proliferating through exposure to ultraviolet light. With more than 1,000 patents secured and verified for the application of Violeds technology, the company has succeeded in extending its lifespan of its UV LED devices to 50,000 hours, and they have been widely adopted for air conditioners, air purifiers, water purifiers and multi-disinfection devices.
About Seoul Viosys
Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Micro Clean Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2018). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Micro Clean Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005326/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
